Literature DB >> 10746730

Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1.

L Gu1, S Tseng, R M Horner, C Tam, M Loda, B J Rollins.   

Abstract

Activated T lymphocytes differentiate into effector cells tailored to meet disparate challenges to host integrity. For example, type 1 and type 2 helper (T(H)1 and T(H)2) cells secrete cytokines that enhance cell-mediated and humoral immunity, respectively. The chemokine monocyte chemoattractant protein-1 (MCP-1) can stimulate interleukin-4 production and its overexpression is associated with defects in cell-mediated immunity, indicating that it might be involved in T(H)2 polarization. Here we show that MCP-1-deficient mice are unable to mount T(H)2 responses. Lymph node cells from immunized MCP-1(-/-) mice synthesize extremely low levels of interleukin-4, interleukin-5 and interleukin-10, but normal amounts of interferon-gamma and interleukin-2. Consequently, these mice do not accomplish the immunoglobulin subclass switch that is characteristic of T(H)2 responses and are resistant to Leishmania major. These effects are direct rather than due to abnormal cell migration, because the trafficking of naive T cells is undisturbed in MCP-1(-/-) mice despite the presence of MCP-1-expressing cells in secondary lymphoid organs of wild-type mice. Thus, MCP-1 influences both innate immunity, through effects on monocytes, and adaptive immunity, through control of T helper cell polarization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746730     DOI: 10.1038/35006097

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  229 in total

Review 1.  Gene targeting of chemokines and their receptors.

Authors:  D M Slattery; N Gerard; C Gerard
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Regulation of Th1 and Th2 immune responses by chemokines.

Authors:  H Yoneyama; S Kawasaki; K Matsushima
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Chemokines: the times they are a-changin'.

Authors:  G Márquez; C Martínez-A
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 4.  Chemokines in allergic lung inflammation.

Authors:  Clare Lloyd
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 5.  Cytokines in innate host defense in the lung.

Authors:  Robert M Strieter; John A Belperio; Michael P Keane
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

6.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

7.  Interleukin-12 regulates chemokine gene expression during the early immune response to Leishmania major.

Authors:  Colby Zaph; Phillip Scott
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

8.  Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice.

Authors:  Tie Liu; Tetsuya Matsuguchi; Naotake Tsuboi; Toshiki Yajima; Yasunobu Yoshikai
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

9.  Polarization of allogeneic T-cell responses by influenza virus-infected dendritic cells.

Authors:  Sangkon Oh; Maryna C Eichelberger
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

10.  Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4+ lymphocytes.

Authors:  Amy Murphy; Jen-Hwa Chu; Mousheng Xu; Vincent J Carey; Ross Lazarus; Andy Liu; Stanley J Szefler; Robert Strunk; Karen Demuth; Mario Castro; Nadia N Hansel; Gregory B Diette; Becky M Vonakis; N Franklin Adkinson; Barbara J Klanderman; Jody Senter-Sylvia; John Ziniti; Christoph Lange; Tomi Pastinen; Benjamin A Raby
Journal:  Hum Mol Genet       Date:  2010-09-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.